Oslo, 8 April 2026: Circio Holding ASA (the “Company”) hereby announces its preliminary and unaudited financial highlights and an overview of key events for the second half of 2025, as well as certain post-period events year-to-date 2026.
Key highlights and events include:
- Up to 40-fold enhanced AAV expression in heart tissue in vivo (circVec generation 3.2), with circVec generation 4 achieving a further 50% boost over generation 3.2
- New in vivo data post-period showing up to 50-fold enhanced circVec-AAV gene expression in eye
- Fully funded feasibility study on circVec AAV gene therapy entered with a top 5 global pharmaceutical corporation
- New research collaborations established with The University of Texas Medical Branch (infectious diseases) and United Immunity Co. (in vivo CAR-Macrophage therapy)
- Rights issue completed in Q1 2026 with more than 50% over-subscription, raising total gross proceeds of approximately NOK 68.6 million
- Net cash balance as of 31 March 2026 of NOK 42 million
- Abstract selected for oral presentation at the ASGCT annual meeting in Boston, May 2026
More detailed information about key events and developments, as well as preliminary and unaudited financial information, including the Group's profit and loss for 2H2025 and net cash position as of 31 December 2025, and a going concern assessment can be found in the attached presentation.
The Annual Report for 2025 will be published on 15 April 2026.